^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    zoledronic acid

    i
    Other names: CGP 42446, ZOL 446, CGP 42446A, AK-156
    Company:
    Generic mfg.
    Drug class:
    Osteoclast inhibitor, Bone resorption factor inhibitor
    Related drugs:
    3d
    ZAPOA: Altering Bone Microarchitecture and Mechanics by Off-label Pharmaceutical Intervention Following an Acute Knee Injury (clinicaltrials.gov)
    P1, N=4, Terminated, University of Calgary | N=56 --> 4 | Trial completion date: Dec 2024 --> Jul 2025 | Recruiting --> Terminated | Trial primary completion date: Dec 2024 --> Jul 2025; Recruitment stopped due to funding shortage. The scope of the original study increased beyond what had been budgeted in the grant that funded it, and follow-up funding attempts were not successful.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    zoledronic acid
    4d
    Switching from Zoledronic Acid to Denosumab for Bone Modification Therapy in Patients with Malignant Tumors and Renal Insufficiency: A Retrospective Case Series and Literature Review. (PubMed, Case Rep Oncol)
    Patients with abnormal renal function, BRCA1 mutations, or those at high risk of developing skeletal-related events may benefit from denosumab over zoledronic acid. During denosumab treatment in patients with renal dysfunction, attention should be paid to the occurrence of hypocalcemia.
    Retrospective data • Journal • BRCA Biomarker
    |
    BRCA1 (Breast cancer 1, early onset)
    |
    Prolia (denosumab) • zoledronic acid
    10d
    Late Diagnosis of Hyperphosphatemic Familial Tumoral Calcinosis in an Adult Male: Lessons from a Misclassified Case. (PubMed, Mod Rheumatol Case Rep)
    The patient was started on a low phosphate diet, sevelamer, and acetazolamide and was instructed to avoid calcium and vitamin D supplements. Intravenous Zoledronic Acid was also given. The patient reported improvement in his symptoms in the follow-up visits.
    Journal
    |
    FGF23 (Fibroblast Growth Factor 23)
    |
    zoledronic acid • acetazolamide
    16d
    IPIZA: Intraperitoneal Immune Checkpoint Inhibitors and Zoledronic Acids for Gastric Cancer Malignant Ascites (clinicaltrials.gov)
    P1/2, N=24, Recruiting, Qilu Hospital of Shandong University | Trial completion date: Feb 2025 --> Sep 2026 | Trial primary completion date: Feb 2025 --> Sep 2026
    Trial completion date • Trial primary completion date • Checkpoint inhibition
    |
    Tyvyt (sintilimab) • zoledronic acid
    16d
    The Optimal Sequential Therapy After Long Term Denosumab Treatment (clinicaltrials.gov)
    P4, N=44, Completed, National Taiwan University Hospital | Recruiting --> Completed
    Trial completion
    |
    Prolia (denosumab) • zoledronic acid
    1m
    The role of immune- and lipid metabolism-related genes in macrophage polarization and prognosis of glioblastoma. (PubMed, Front Oncol)
    Drug sensitivity analysis demonstrated a correlation between LGALS1 expression and the response to agents such as zoledronate and staurosporine. Immune- and lipid metabolism-related genes contribute to macrophage polarization and are closely linked to GBM prognosis. The identified gene signature provides prognostic value and potential therapeutic targets for immunometabolic modulation in GBM.
    Journal
    |
    LGALS1 (Galectin 1) • FABP5 (Fatty Acid Binding Protein 5)
    |
    zoledronic acid
    2ms
    γδ T cells in prostate cancer. (PubMed, Int Rev Cell Mol Biol)
    Recent advances in γδ T cell-based immunotherapies, particularly in combination with agents such as zoledronate bisphosphonate that enhances tumor recognition, show promising preclinical results. However, obstacles such as the suppressive tumor microenvironment and immune evasion mechanisms remain significant. This chapter highlights the therapeutic potential of γδ T cells in prostate cancer and the need for further research to optimize these approaches.
    Review • Journal
    |
    IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha)
    |
    zoledronic acid
    2ms
    Anti-HER2/Neu Antibody Therapy Inhibits HER2+ Breast Cancer by Blocking Myeloid-Derived Suppressor Cell Activity. (PubMed, Oncol Res Treat)
    Tumor suppression by anti-neu antibody is associated with MDSC reduction via inhibition of key MDSC-related factors. MDSCs may be a therapeutic target to enhance Herceptin efficacy in breast cancer.
    Journal • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • ITGAM (Integrin, alpha M) • CX3CL1 (C-X3-C Motif Chemokine Ligand 1) • IL1B (Interleukin 1, beta)
    |
    Herceptin (trastuzumab) • 5-fluorouracil • zoledronic acid
    2ms
    Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors (clinicaltrials.gov)
    P1, N=22, Recruiting, University of Wisconsin, Madison | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    melphalan • fludarabine IV • zoledronic acid
    2ms
    Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone (clinicaltrials.gov)
    P3, N=120, Recruiting, St. Louis University | Trial completion date: Jan 2027 --> Jan 2028 | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial completion date • Trial primary completion date
    |
    zoledronic acid
    2ms
    Treatment With Zoledronate Subsequent to Denosumab in Osteoporosis 2 (ZOLARMAB2) (clinicaltrials.gov)
    P4, N=200, Active, not recruiting, Aarhus University Hospital | Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2025 --> Feb 2027
    Enrollment closed • Trial primary completion date
    |
    DKK1 (dickkopf WNT signaling pathway inhibitor 1)
    |
    Prolia (denosumab) • zoledronic acid
    2ms
    Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors (clinicaltrials.gov)
    P1/2, N=27, Recruiting, University of Florida | Initiation date: Aug 2025 --> Nov 2025
    Trial initiation date
    |
    zoledronic acid